Sarepta Therapeutics (SRPT) Revenue (2012 - 2026)

Sarepta Therapeutics has reported Revenue for 13 years, with the latest figure at $400.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 200.22% year-over-year to $400.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 14.29% YoY), and the FY2025 full-year result was $2.2 billion, up 15.58% from the prior year.
• Revenue for Q1 2026 stood at $400.3 million, down from $442.9 million in the prior quarter.
• The five-year high for Revenue was $658.4 million in Q4 2024, with the low at $22.0 million in Q1 2022.
• Average Revenue over 5 years is $327.7 million, with a median of $362.9 million recorded in 2024.
• Year-over-year, Revenue slumped 89.46% in 2023 and surged 1531.15% in 2024.
• Tracing SRPT's Revenue over 5 years: stood at $169.2 million in 2022, then soared by 173.98% to $463.5 million in 2023, then surged by 42.04% to $658.4 million in 2024, then plunged by 32.73% to $442.9 million in 2025, then dropped by 9.63% to $400.3 million in 2026.
• The last three Revenue figures came in at $400.3 million (Q1 2026), $442.9 million (Q4 2025), and $399.4 million (Q3 2025), per Business Quant data.

Peer Comparison